Bispecific Monoclonal Antibody - Cancer Science

Relevant Publications

Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.

Issue Release: 2024

Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1.

Issue Release: 2024

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study.

Issue Release: 2024

Matching-adjusted indirect comparisons of axicabtagene ciloleucel to mosunetuzumab for the treatment of relapsed/refractory follicular lymphoma.

Issue Release: 2024

Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review.

Issue Release: 2024

Tolerance of radiotherapy with concomitant glofitamab in diffuse large B cell lymphoma: a case report.

Issue Release: 2024

Immune-related adverse events of antibody-based biological medicines in cancer therapy.

Issue Release: 2024

Pretargeted Radioimmunotherapy with the Novel Anti-oxMIF/HSG Bispecific Antibody ON105 Results in Significant Tumor Regression in Murine Models of Cancer.

Issue Release: 2024

PHE1-based IgG-like antibody platform provides a novel strategy for enhanced T-cell immunotherapy.

Issue Release: 2024

Characterization of anti-drug antibody responses to the T-cell engaging bispecific antibody cibisatamab to understand the impact on exposure.

Issue Release: 2024

Glofitamab-Associated Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Presenting as Serial Seizures and Responding Positively to Antiseizure Drugs and Anakinra: A Case Report.

Issue Release: 2024

A bispecific antibody that targets the membrane-proximal region of mesothelin and retains high anticancer activity in the presence of shed mesothelin.

Issue Release: 2024

T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies.

Issue Release: 2024

Balancing the Affinity and Tumor Cell Binding of a Two-in-One Antibody Simultaneously Targeting EGFR and PD-L1.

Issue Release: 2024

Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice.

Issue Release: 2024

Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody.

Issue Release: 2024

State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies.

Issue Release: 2024

A dual-targeting approach using a human bispecific antibody against the receptor-binding domain of the Middle East Respiratory Syndrome Coronavirus.

Issue Release: 2024

Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern.

Issue Release: 2024

Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review.

Issue Release: 2024

What Impact Do Advocates Have on Patient Outcomes?

What are Top-Up Plans?

What Can Patients Do to Access Affordable Treatments?

How Can Dimensionality Reduction Improve Cancer Diagnosis?

How Does MHC Class II Presentation Work?

How Can Support Systems Influence Life Expectancy?

Can MHC Class I Expression Be Modulated for Cancer Therapy?

What Are Targeted Therapies in Cancer Treatment?

What are the Safety Guidelines for SAR?

Why is LDHA Important in Cancer?

Partnered Content Networks

Relevant Topics